Article information
Since the discovery of antibiotics, it has been generally believed that these antimicrobials are capable of curing almost all bacterial infections. More recently, the appearance of increasing resistance to antibiotics and the emergence of multiresistant microorganisms have given rise to growing concern among physicians, and that concern has now started to filter through to society in general. The problem is further aggravated by a situation that not many people are currently aware of, that is, the limited prospects for future development of new antibiotics in the short to medium term. Appropriate use of available antibiotics based on a thorough understanding of their in vivo activity and the emergence of new forms of administration, such as inhalers, may help to alleviate the problem.
Key words:
Antibiotics
Respiratory infection
Resistance
Desde el descubrimiento de los antibióticos se tenía la creencia generalizada de que eran capaces de curar casi la totalidad de las infecciones bacterianas. Desde entonces, la aparición y el incremento de resistencias a los antimicrobianos y la constatación de la emergencia de microorganismos multi- rresistentes han generado entre los médicos una preocupación creciente, que empieza a trascender a la sociedad. La escasa perspectiva de desarrollo de nuevos fármacos anti- bióticos a corto-medio plazo es poco conocida y agrava el problema. El aprovechamiento de los antibióticos disponibles, mediante el conocimiento en profundidad de su actividad in vivo, así como la emergencia de nuevas formas de administración como la inhalada, puede ayudar a paliar el problema.
Palabras clave:
Antibióticos
Infección respiratoria
Resistencias
Full text is only available in PDF
REFERENCES
[1]
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003.
Am J Infect Control, 31 (2003), pp. 481-498
[2]
Centers for Disease Control and Prevention (CDC).
Vancomycin-resistant Staphylococcus aureus.
MMWR Morb Mortal Wkly Rep, 53 (2004), pp. 322-323
[3]
A Asensio, R Canton, J Vaque, J Roselló, F Calvo, J García-Caballero, EPINE Working Group, et al.
Nosocomial and community- acquired methicillin-resistant Staphylococcus aureus infections in hospitalized patients (Spain, 1993-2003).
J Hosp Infect, 63 (2006), pp. 465-471
[4]
SK Fridkin, JC Hageman, M Morrison, LT Sanza, K Como-Sabetti, JA Jernigan, et al.
Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in three communities.
N Engl J Med, 352 (2005), pp. 1436-1444
[5]
SH Zinner.
The search for new antimicrobials: why we need new options.
Expert Rev Anti Infect Ther, 3 (2005), pp. 907-913
[6]
AA Shah, F Hasan, S Ahmed, A Hameed.
Characteristics, epidemiology and clinical importance of emerging strains of Gram negative bacilli producing extended-spectrum beta-lactamases.
Res Microbiol, 155 (2004), pp. 409-421
[7]
CI Kang, SH Kim, WB Park, KD Lee, HB Kim, EC Kim, et al.
Bloodstream infections due to extended-spectrum b-lactamase- producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Antimicrob Agents Chemother, 48 (2004), pp. 4574-4581
[8]
J Rodríguez-Bano, MD Navarro, L Romero, L Martínez-Martínez, MA Muniain, EJ Perea, et al.
Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients.
J Clin Microbiol, 42 (2004), pp. 1089-1094
[9]
R Colodner, W Rock, B Chazan, N Keller, N Guy, W Sakran, et al.
Risk factors for the development of extended-spectrum beta-lactamase- producing bacteria in nonhospitalized patients.
Eur J Clin Microbiol Infect Dis, 23 (2004), pp. 163-167
[10]
DW Hetch.
Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments.
Clin Infect Dis, 39 (2004), pp. 92-97
[11]
E Pérez-Trallero, C García de la Fuente, C García-Rey, F Baquero, L Aguilar, R Dal-Ré, The Spanish Surveillance Group for Respiratory Pathogens, et al.
Geographical and ecological analysis of resistance, coresistance and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain.
Antimicrob Agents Chemother, 49 (2005), pp. 1965-1972
[12]
M Hotomi, K Fujihara, A Sakai, DS Billal, J Shimada, M Suzumoto, et al.
Antimicrobial resistance of Haemophilus influenzae isolated from the nasopharynx of Japanese children with acute otitis media.
Acta Otolaryngol, 126 (2006), pp. 240-247
[13]
F Soriano.
Importancia de los parámetros farmacocinéticos y farmacodinámicos en la elección del tratamiento antimicrobiano de la infección respiratoria.
Med Clin Monogr (Barc), 5 (2004), pp. 6-11
[14]
F Soriano, JJ Granizo, A Fenoll, M Gracia, R Fernández-Roblas, J Esteban, et al.
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four Southern European countries (ARISE Project) from adult patients: results from the Cefditoren Surveillance Program.
J Chemother, 15 (2003), pp. 107-112
[15]
M Miravitlles, J Molina, M Brosa.
Eficacia clínica del moxifloxacino en el tratamiento de las agudizaciones de la bronquitis crónica. Revisión sistemática y metaanálisis.
Arch Bronconeumol, 43 (2007), pp. 22-28
[16]
MJ Giménez, ML Gómez-Lus, L Valdés, L Aguilar.
Situación de la cefalosporina oral de tercera generación cefditoreno pivoxil en el tratamiento de la infección comunitaria del adulto.
Rev Esp Quimioter, 18 (2005), pp. 210-216
[17]
JJ Granizo, L Aguilar, J Casal, C García-Rey, R Dal-Ré, F Baquero.
Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997).
J Antimicrob Chemother, 46 (2000), pp. 767-773
[18]
J Garau.
Treatment of drug-resistant pneumococcal pneumonia.
Lancet Infect Dis, 2 (2002), pp. 404-415
[19]
R Pallarés, J Liñares, M Vadillo, C Cabellos, F Manresa, PF Viladrich, et al.
Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.
N Engl J Med, 333 (1995), pp. 474-480
[20]
T Bauer, S Ewig, MA Marcos, G Schultze-Werninghaus, A Torres.
Streptococcus pneumoniae in community-acquired pneumonia. How important is drug resistance?.
Med Clin North Am, 85 (2001), pp. 1367-1379
[21]
KP Klugman.
Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections.
Eur Respir J, 20 (2002), pp. 3-8
[22]
JP Metlay, J Hofmann, MS Cetron, MJ Fine, MM Farley, C Whitney, et al.
Impact of penicillin susceptibility on medical outcomes for adult patients with bacteriemic pneumococcal pneumonia.
Clin Infect Dis, 30 (2000), pp. 520-528
[23]
TM File, MR Jacobs, MD Poole, B Wynne.
Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxicillin/clavulanate.
Int J Antimicrob Agent, 20 (2002), pp. 235-247
[24]
J Garau, M Twynholm, E García-Méndez, B Siquier, A Rivero.
557 Clinical Study Group. Oral pharmacokinetically enhanced coamoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
J Antimicrob Chemother, 52 (2003), pp. 826-836
[25]
B Siquier, J Sánchez-Álvarez, E García-Méndez, M Sabriá, J Santos, R Pallarés, et al.
Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
J Antimicrob Chemother, 57 (2006), pp. 536-545
[26]
JR Lonks, J Garau, L Gómez, M Xercavins, A Ochoa de Echagüen, IF Gareen, et al.
Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae.
Clin Infect Dis, 35 (2002), pp. 556-564
[27]
R Leclercq, P Courvalin.
Resistance to macrolides and related antibiotics in Streptococcus pneumoniae.
Antimicrob Agents Chemother, 46 (2002), pp. 2727-2734
[28]
C Fogarty, R Goldschmidt, K Bush.
Bacteriemic pneumonia due to multidrug resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and clarithromycin.
Clin Infect Dis, 31 (2000), pp. 613-615
[29]
MA Kelley, DJ Weber, P Gilligan, MS Cohen.
Breakthrough pneumococcal bacteriemia in patients being treated with azithromycin and clarithromycin.
Clin Infect Dis, 31 (2000), pp. 1008-1011
[30]
GW Waterer, RG Wunderink, CB Jones.
Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy.
Chest, 118 (2000), pp. 1839-1840
[31]
I Alfageme, J Aspa, S Bello, J Blanquer, R Blanquer, L Borderías, et al.
Grupo de Estudio de la Neumonía Adquirida en la Comunidad. Área de Tuberculosis e Infecciones Respiratorias (TIR)-SEPAR. Normativas para el diagnóstico y el tratamiento de la neumonía adquirida en la comunidad.
Arch Bronconeumol, 41 (2005), pp. 272-289
[32]
K Weiss, C Guilbault, L Cortes, C Restieri, DE Low, the EQUERE Project.
Genotypic characterization of macrolide-resistant strains of Streptococcus pneumoniae isolated in Quebec, Canada, and in vitro activity of ABT-773 and telithromycin.
J Antimicrob Chemother, 50 (2002), pp. 403-406
[33]
G Ackermann, AC Rodloff.
Drugs of the 21st century: telithromycin (HMR 3647) – the first ketolide.
J Antimicrob Chemother, 51 (2003), pp. 497-511
[34]
DB Ross.
The FDA and the Case of Ketek.
N Engl Med, 356 (2007), pp. 1601-1604
[35]
Office Press.
European Medicines Agency. Doc. Ref. EMEA/129901/2007.
[36]
MS Niederman.
Recent advances in community-acquired pneumonia. Inpatient and outpatient.
Chest, 131 (2007), pp. 1205-1215
[37]
S Brown, DJ Farrell.
Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002.
J Antimicrob Chemother, 54 (2004), pp. 23-29
[38]
O Cars, S Molstad, A Melander.
Variation in antibiotic use in the European Union.
Lancet, 357 (2001), pp. 1851-1853
[39]
RN Jones.
Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001).
Semin Respir Crit Care Med, 24 (2003), pp. 121-134
[40]
M Gobernado, J Honorato.
Content clinical monograph: moxifloxacino en infecciones respiratorias, Communications SL, (2006),
[41]
C García-Rey, JE Martín-Herrero, F Baquero.
Antibiotic consumption and generation of resistance in Streptococcus pneumoniae: the paradoxical impact of quinolones in a complex selective landscape.
Clin Microb Infec, 12 (2006), pp. 55-66
[42]
LM Deshpande, HS Sader, E Debbia, G Nicoletti, G Fadda, RN Jones.
SENTRY Antimicrobial Surveillance Program (2001-2004). Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).
Diagn Microbiol Infect Dis, 54 (2006), pp. 157-164
[43]
MR Marín, JL Muñoz, JA García.
Risk factors associated with colonization by pneumococci with reduced susceptibility to fluoroquinolones in adult outpatients.
J Clin Microbiol, 43 (2005), pp. 1193-1197
[44]
PL Ho, WS Tse, KWT Tsang, TK Kwook, TK Ng, VCC Cheng, et al.
Factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.
Clin Infect Dis, 32 (2001), pp. 01-07
[45]
S Bello, A Torres.
Neumococo y resistencia a quinolonas.
Arch Bronconeumol, 39 (2003), pp. 97-100
[46]
MP Palacián, M Arias, B Moles, C Villuendas, MJ Revillo.
S. pneumoniae: resistencia a flouroquinolonas. Estudio de los datos microbiológicos y clínicos.
Enf Infecc Microbiol Clin, 24 (2006), pp. 155
[47]
R Davidson, R Cavalcanti, JL Brunton, DJ Bast, JC De Azavedo, P Kisbey, et al.
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
N Engl J Med, 346 (2002), pp. 747-750
[48]
AB Carcavilla, F López-Medrano, F Chaves, V Villena, J Echave-Sustaeta, JM Aguado.
Fracaso del tratamiento con levofloxacino en dos casos de neumonía de la comunidad por Streptococcus pneumoniae resistente a fluoroquinolonas y complicado con empiema.
Enf Infecc Microbiol Clin, 23 (2005), pp. 270-273
[49]
PE Empey, HR Jennings, AC Thornton, RP Rapp, ME Evans.
Levofloxacin failure in a patient with pneumococcal pneumonia.
Ann Pharmacother, 35 (2001), pp. 687-690
[50]
GM Eliopoulos.
Quinolone resistance mechanisms in pneumococci.
Clin Infect Dis, 38 (2004), pp. 350-356
[51]
MWR Pletz, AP Shergill, LM McGee, B Beall, CG Whitney, KP Klugman.
Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United States.
Antimicrob Agents Chemother, 50 (2006), pp. 1561-1563
[52]
TA Davies, A Evangelista, S Pfleger, K Bush, DF Sham, R Goldschmidt.
Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000.
Antimicrob Agents Chemother, 46 (2002), pp. 119-124
[53]
HJ Smith, M Walters, T Hisanaga, GG Zhanel, DJ Hoban.
Mutant prevention concentrations for single-step fluoroquinolone resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation- containing Streptococcus pneumoniae isolates.
Antimicrob Agents Chemother, 48 (2004), pp. 3954-3958
[54]
KN Schurk, HJ Adam, CG Siemens, CJ Hoban, DJ Hoban, GG Zhanel.
Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
J Antimicrob Chemother, 56 (2005), pp. 769-772
[55]
DP Nicolau.
Antibiotic kinetic and dynamic attributes for community- acquired respiratory tract infections.
Am J Manag Care, 6 (2000), pp. 1202-1210
[56]
E Pérez-Trallero, C García-Rey, AM Martín-Sánchez, L Aguilar, J García de Lomas, J Ruiz.
Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain.
Antimicrob Agent Chemother, 46 (2002), pp. 2265-2267
[57]
JD Heffelfinger, SF Dowell, JH Jorgensen, KP Klugman, LR Mabry, DM Musher, et al.
Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
Arch Intern Med, 160 (2000), pp. 1399-1480
[58]
GG Zhanel, K Homenulk, K Nichol, A Noreddin, L Vercaigne, J Embil, et al.
The glycylcyclines: a comparative review with the tetracyclines.
Drugs, 64 (2004), pp. 63-88
[59]
K Bush, M Macielag, M Weider-Wells.
Taking inventory: antibacterial agents currently at or beyond phase 1.
Curr Opin Microbiol, 7 (2004), pp. 466-476
[60]
DR Guay.
Dalbavancin: an investigational glycopeptide.
Expert Rev Anti Infect Ther, 2 (2004), pp. 845-852
[61]
RC Mercier, L Hrebickova.
Oritavancin: a new avenue for resistant Gram-positive bacteria.
Expert Rev Anti Infect Ther, 3 (2005), pp. 325-332
[62]
JL Pace, JK Judice.
Telavancin (Theravance).
Curr Opin Investig Drugs, 6 (2005), pp. 216-225
[63]
M Christ-Crain, D Stolz, R Bingisser, C Muller, D Miedinger, PR Huber, et al.
Procalcitonin Guidance of Antibiotic Therapy in Community- acquired Pneumonia: A Randomized Trial.
Am J Respir Crit Care Med, 174 (2006), pp. 84-93
[64]
JM Aguado-García, JE Martín-Herrero, C Lumbreras-Bermejo.
Resistencias bacterianas y farmacodinámica como bases de la prescripción de antibióticos en las infecciones respiratorias.
Enferm Infecc Micobiol Clin, 22 (2004), pp. 230-237
[65]
P Ball, F Baquero, O Cars, T File, J Garau, K Klugman, Consensus Group on Resistance and Prescribing in Respiratory Tract Infection, et al.
Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence.
J Antimicrob Chemother, 49 (2002), pp. 31-40
[66]
R Dagan, KP Klugman, WA Craig, F Baquero.
Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy.
J Antimicrob Ther, 47 (2001), pp. 129-140
[67]
JC Pechère, L Lacey.
Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis.
J Antimicrob Chemother, 45 (2000), pp. 19-24
[68]
J Mensa.
Farmacocinética/farmacodinamia de las principales familias de antibióticos.
Doyma Update: Patología Infecciosa Respiratoria, pp. 5-15
[69]
DP Nicolau.
Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling.
J Infect Chemother, 9 (2003), pp. 292-296
[70]
BW Ramsey, MS Pepe, JM Quan, KL Otto, AB Montgomery, J Williams-Warren, et al.
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
N Engl J Med, 340 (1999), pp. 23-30
[71]
B Heinzl, E Eber, B Oberwaldner, G Haas, MS Zach.
Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study.
Pediatr Pulmonol, 33 (2002), pp. 32-37
[72]
I MacLusky, H Levison, R Gold, FJ McLaughlin.
Inhaled antibiotics in cystic fibrosis: is there a therapeutic effect?.
J Pediatr, 108 (1986), pp. 861-865
[73]
G Nolan, P Moivor, H Levison, PC Fleming, M Corey, R Gold.
Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin.
J Pediatr, 101 (1982), pp. 626-630
[74]
AL Smith.
Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation?.
J Cyst Fibros, 1 (2002), pp. 189-193
[75]
C Toso, DM Williams, PG Noone.
Inhaled antibiotics in cystic fibrosis: a review.
Ann Pharmacother, 30 (1996), pp. 840-850
[76]
DF Wittenberg.
Maintenance of Pseudomonas antibiotic sensitivity in patients with cystic fibrosis treated with inhaled antibiotics.
S Afr Med J, 71 (1987), pp. 335-336
[77]
P Wunderlich, KD Paul, J Wehner.
Value of inhaled antibiotics in cystic fibrosis patients.
Acta Univ Carol, 36 (1990), pp. 34-36
[78]
VN Ahya, AM Doyle, JD Méndez, DA Lipson, JD Christie, EA Blumberg, et al.
Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient.
J Heart Lung Transplant, 24 (2005), pp. 932-935
[79]
GA Alothman, B Ho, MM Alsaadi, SL Ho, L O'Drowsky, E Louca, et al.
Bronchial constriction and inhaled colistin in cystic fibrosis.
Chest, 127 (2005), pp. 522-529
[80]
GA Alothman, MM Alsaadi, BL Ho, SL Ho, A Dupuis, M Corey, et al.
Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin.
Chest, 122 (2002), pp. 930-934
[81]
D Banerjee, D Stableforth.
The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?.
Drugs, 60 (2000), pp. 1053-1064
[82]
P Beringer.
The clinical use of colistin in patients with cystic fibrosis.
Curr Opin Pulm Med, 7 (2001), pp. 434-440
[83]
PM Beringer.
New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis.
Curr Opin Pulm Med, 5 (1999), pp. 371-377
[85]
CM Bowman.
The long-term use of inhaled tobramycin in patients with cystic fibrosis.
J Cyst Fibros, 1 (2002), pp. 194-198
[86]
JL Burns, JM van Dalfsen, RM Shawar, KL Otto, RL Garber, JM Quan, et al.
Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
J Infect Dis, 179 (1999), pp. 1190-1196
[87]
SM Cheer, J Waugh, S Noble.
Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Drugs, 63 (2003), pp. 2501-2520
[88]
A Clavel, A Boulamery, E Bosdure, C Luc, A Lanteaume, G Gorincour, et al.
Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis.
J Cyst Fibros, 11 (2006), pp. 265-267
[89]
AL Coates, CF MacNeish, D Meisner, S Kelemen, R Thibert, J MacDonald, et al.
The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols.
Chest, 111 (1997), pp. 1206-1212
[90]
PJ Cole.
The role of nebulized antibiotics in treating serious respiratory infections.
J Chemother, 13 (2001), pp. 354-362
[91]
NR Crowther Labiris, AM Holbrook, H Chrystyn, SM Macleod, MT Newhouse.
Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study.
Am J Respir Crit Care Med, 160 (1999), pp. 1711-1716
[92]
P Diot, F Gagnadoux, C Martin, H Ellataoui, Y Furet, M Breteau, et al.
Nebulization and anti-Pseudomonas aeruginosa activity of colistin.
Eur Respir J, 10 (1997), pp. 1995-1998
[93]
ME Dodd, J Abbott, J Maddison, AJ Moorcroft, AK Webb.
Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis.
Thorax, 52 (1997), pp. 656-658
[95]
RS Edson, RH Brey, TJ McDonald, CL Terrell, JT McCarthy, JM Thibert.
Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency.
Mayo Clin Proc, 79 (2004), pp. 1185-1191
[96]
RJ Stead, ME Hodson, JC Batten.
Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa.
Br J Dis Chest, 81 (1987), pp. 272-279
[97]
MA Wall, AB Terry, J Eisenberg, M McNamara, R Cohen.
Inhaled antibiotics in cystic fibrosis.
Lancet, 1 (1983), pp. 1325
[98]
RB Moss.
Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.
Chest, 121 (2002), pp. 55-63
[99]
G Ryan, S Mukhopadhyay, M Singh.
Nebulised anti-pseudomonal antibiotics for cystic fibrosis.
Cochrane Database Syst Rev, (2003), pp. CD001021
[100]
DM Wood, AR Smyth.
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Cochrane Database Syst Rev, (2006), pp. CD004197
[101]
AF Barker, L Couch, SB Fiel, MH Gotfried, J Ilowite, KC Meyer, et al.
Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis.
Am J Respir Crit Care Med, 162 (2000), pp. 481-485
[102]
E Caballero, ME Drobnic, MT Pérez, JM Manresa, A Ferrer, R Orriols.
Anti-Pseudomonas aeruginosa antibody detection in patients with bronchiectasis without cystic fibrosis.
Thorax, 56 (2001), pp. 669-674
[103]
ME Drobnic, P Sune, JB Montoro, A Ferrer, R Orriols.
Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
Ann Pharmacother, 39 (2005), pp. 39-44
[104]
R Orriols, J Roig, J Ferrer, G Sampol, A Rosell, A Ferrer, et al.
Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa.
Respir Med, 93 (1999), pp. 476-480
[105]
S Nakamura, K Yanagihara, Y Morinaga, H Ohno, Y Higashiyama, et al.
Case reports of the treatment with tobramycin solution for inhalation in severe bronchiectasis patients continuous infection of Pseudomonas aeruginosa.
Nihon Kokyuki Gakkai Zasshi, 43 (2005), pp. 41-47
[106]
DE Geller, WH Pitlick, PA Nardella, WG Tracewell, BW Ramsey.
Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.
Chest, 122 (2002), pp. 219-226
[107]
S Sethi, J Maloney, L Grove, C Wrona, CS Berenson.
Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 173 (2006), pp. 991-998
[108]
A Bush, BK Rubin.
Macrolides as biological response modifiers in cystic fibrosis and bronchiectasis.
Semin Respir Crit Care Med, 24 (2003), pp. 737-748
[109]
GW Amsden.
Anti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?.
J Antimicrob Chemother, 55 (2005), pp. 10-21
[110]
U Baumann, M King, EM App, S Tai, A Konig, JJ Fischer, et al.
Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties.
Can Respir J, 11 (2004), pp. 151-155
[111]
SC Bell, SL Senini, JG McCormack.
Macrolides in cystic fibrosis.
Chron Respir Dis, 2 (2005), pp. 85-98
[112]
A Clement, A Tamalet, RE Le, S Ravilly, B Fauroux, JP Jais.
Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial.
Thorax, 61 (2006), pp. 895-902
[113]
SP Conway, KG Brownlee, M Denton, DG Peckham.
Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.
Am J Respir Med, 2 (2003), pp. 321-332
[114]
R Dinwiddie.
Anti-inflammatory therapy in cystic fibrosis.
J Cyst Fibros, 4 (2005), pp. 45-48
[116]
G Ferrara, M Losi, F Franco, L Corbetta, LM Fabbri, L Richeldi.
Macrolides in the treatment of asthma and cystic fibrosis.
Respir Med, 99 (2005), pp. 1-10
[117]
AS Gaylor, JC Reilly.
Therapy with macrolides in patients with cystic fibrosis.
Pharmacotherapy, 22 (2002), pp. 227-239
[118]
CL Maiz, MR Canton.
Tratamiento con azitromicina en fibrosis quística.
Med Clin (Barc), 122 (2004), pp. 311-316
[119]
Y Majima.
Clinical implications of the immunomodulatory effects of macrolides on sinusitis.
Am J Med, 117 (2004), pp. 20-25
[120]
JC Pechere.
New perspectives on macrolide antibiotics.
Int J Antimicrob Agents, 18 (2001), pp. 93-97
[122]
KW Southern, PM Barker, A Solis.
Macrolide antibiotics for cystic fibrosis.
Cochrane Database Syst Rev, (2000), pp. CD002203
[123]
D Spencer.
Macrolide antibiotics in diffuse panbronchiolitis and in cystic fibrosis.
Eur Respir J, 11 (1998), pp. 1428
[124]
WE Swords, BK Rubin.
Macrolide antibiotics, bacterial populations and inflammatory airway disease.
Neth J Med, 61 (2003), pp. 242-248
[125]
MR Tonelli, ML Aitken.
New and emerging therapies for pulmonary complications of cystic fibrosis.
Drugs, 61 (2001), pp. 1379-1385
[126]
JM Wolter, SL Seeney, JG McCormack.
Macrolides in cystic fibrosis: is there a role?.
Am J Respir Med, 1 (2002), pp. 235-241
[127]
Y Imamura, K Yanagihara, Y Mizuta, M Seki, H Ohno, Y Higashiyama, et al.
Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-oxodode-canoyl) homoserine lactone in NCI-H292 cells.
Antimicrob Agents Chemother, 48 (2004), pp. 3457-3461
[128]
KW Garey, A Alwani, LH Danziger, I Rubinstein.
Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases.
Chest, 123 (2003), pp. 261-265
[130]
E Drenkard, FM Ausubel.
Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation.
Nature, 416 (2002), pp. 740-743
[131]
TD Starner, N Zhang, G Kim, MA Apicella, PB McCray Jr.
Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis.
Am J Respir Crit Care Med, 174 (2006), pp. 213-220
[132]
DC Look, CL Chin, LJ Manzel, EE Lehman, AL Humlicek, L Shi, et al.
Modulation of airway inflammation by Haemophilus influenzae isolates associated with chronic obstructive pulmonary disease exacerbation.
Proc Am Thorac Soc, 3 (2006), pp. 482-483
[133]
V Majtan, D Hybenova.
Inhibition of Pseudomonas aeruginosa alginate expression by subinhibitory concentrations of antibiotics.
Folia Microbiol (Praha), 41 (1996), pp. 61-64
[134]
ML Everard, P Sly, S Brenan, G Ryan.
Macrolide antibiotics in diffuse panbronchiolitis and in cystic fibrosis.
Eur Respir J, 10 (1997), pp. 2926
[135]
AC Equi, JC Davies, H Painter, S Hyde, A Bush, DM Geddes, et al.
Exploring the mechanisms of macrolides in cystic fibrosis.
Respir Med, 100 (2006), pp. 687-697
[136]
CR Hansen, T Pressler, C Koch, N Hoiby.
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
J Cyst Fibros, 4 (2005), pp. 35-40
[137]
GW Amsden.
Anti-inflammatory effects of macrolides–an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?.
J Antimicrob Chemother, 55 (2005), pp. 10-21
[138]
V Asgrimsson, T Gudjonsson, GH Gudmundsson, O Baldursson.
Novel effects of azithromycin on tight junction proteins in human airway epithelia.
Antimicrob Agents Chemother, 50 (2006), pp. 1805-1812
[139]
A Jaffe, A Bush.
Anti-inflammatory effects of macrolides in lung disease.
Pediatr Pulmonol, 31 (2001), pp. 464-473
[140]
T Kohara, R Susa, Y Tanabe, H Tsukada, E Suzuki, F Shimojyo.
Sino-bronchial syndrome progressed to respiratory failure despite minimal-dose macrolide therapy.
Jpn J Antibiot, 56 (2003), pp. 9-11
[141]
BM Le.
Antibiotic strategy in bronchiectasis in children (mucoviscidosis excepted).
Rev Pneumol Clin, 57 (2001), pp. S18-S21
[142]
J Mazieres.
Antibiotic strategies in bronchiectasis of adults.
Rev Pneumol Clin, 57 (2001), pp. S21-SS5
[143]
BK Rubin, MO Henke.
Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.
Chest, 125 (2004), pp. 70S-78S
[144]
M Vila-Justribo, J Dorca-Sargatal, S Bello-Dronda.
Bronquiectasias y macrólidos.
Arch Bronconeumol, 42 (2006), pp. 206
[145]
MA Martínez García.
Bronquiectasias: ¿todavía una enfermedad huérfana?.
Arch Bronconeumol, 41 (2005), pp. 407-409
[146]
A Capelastegui, PP España, JM Quintana, I Gorordo, C Sañudo, A Bilbao.
Evaluación de la práctica clínica en los pacientes ingresados por neumonía adquirida en la comunidad durante un período de 4 años.
Arch Bronconeumol, 42 (2006), pp. 283-289
[147]
CM Luna, A Monteverde, A Rodríguez, C Apezteguia, G Zabert, S Ilutovich, et al.
Neumonía intrahospitalaria: guía clínica aplicable a Latinoamérica preparada en común por diferentes especialistas.
Arch Bronconeumol, 41 (2005), pp. 439-456
[148]
R Menendez, A Torres, R Zalacain, J Aspa, JJ Martín-Villasclaras, L Borderías, et al.
Guidelines for the Treatment of Community-acquired Pneumonia. Predictors of Adherence and Outcome. Neumofail group.
Am J Respir Crit Care Med, 172 (2005), pp. 757-762
[149]
MH Kyaw, R Lynfield, W Schaffne, AS Craig, J Hadler, A Reingold, for Active Bacterial Core Surveillance of the Emerging Infections Program Network, et al.
Effect of Introduction of the Pneumococcal Conjugate Vaccine on Drug-Resistant Streptococcus pneumonia.
N Engl J Med, 354 (2006), pp. 1455-1463
Copyright © 2007. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
